Amphipathic Octenyl-Alanine Modified Peptides Mediate Effective siRNA Delivery (2025)
Sequence: H-L{R8}KLAKA{R8}AKLLKA{S8}AKAL-NH2
| Experiment Id | EXP001322 |
|---|---|
| Paper | Amphipathic Octenyl-Alanine Modified Peptides Mediate Effective siRNA Delivery |
| Peptide | hPep3 |
| Delivery Success Class | no |
| In Vivo Flag | yes |
| Uptake Confirmed | no |
| Label Confidence | high |
| In Vitro Functional Effect | |
| Endosomal Escape Evidence | |
| Peptide Concentration | |
| Rna Concentration | |
| Mixing Ratio | MR30 (N/P 4.3) |
| Formulation Format | peptide/siRNA nanoparticles (electrostatic complexes) |
| Formulation Components | peptide + siRNA in HBG (HEPES-buffered glucose) / cell culture media; complexes at MR30 |
| Size Nm | 80.00 |
| Zeta Mv | 18.00 |
| Model Scope | in_vivo |
| Model Type | in vivo |
| Cell Lines Or Primary Cells | |
| Animal Model | Female BALB/c mice (~20 g) |
| Administration Route | i.v. (tail vein) |
| Output Type | biodistribution (tissue fluorescence, 4 h) |
| Output Value | Compared with free AF568-siRNA: lungs 7.5×, liver 14.9×, spleen 15.2× higher signal; kidney share ~30% lower |
| Output Units | |
| Output Notes | In vivo biodistribution after i.v. injection of hPep3/AF568-siRNA NPs at MR30, siRNA dose 1 mg/kg; tissues harvested 4 h post-injection and fluorescence quantified from homogenates normalized to total protein. |
| Toxicity Notes | Reported as well tolerated in mice; no functional in vivo knockdown assessed. |
| Curation Notes |